BioSpace News Archive

Oxurion NV, a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, announces its management will participate in the 10th edition of Degroof Petercam’s Healthcare Conference:

AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, announced that an abstract on clinical data of its leading candidate drug ACD856 has been accepted for a poster presentation at AD/PD 2022, which this year will be held in Barcelona on March 15-20.

Sirona Biochem Corp. is pleased to announce that it has renewed an agreement with Luxembourg-based analytics and marketing specialist CURE Intelligence for marketing intelligence services and communications support.

FSD Pharma Inc. warmly congratulates Eleanor N. Fish, Ph.D., a member of its Research and Clinical Advisory Board, on her appointment to the Order of Canada.

Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd. announced the establishment of Dermaliq Therapeutics, Inc, a newly formed Delaware-based pharmaceutical development company, and the signing of a USD 15 million Series A financing round.

Humanigen, Inc. announced a peer-reviewed publication in the Journal of Medical Economics citing the clinical and associated health economic benefits of lenzilumab.

CB Scientific, Inc. announced that the company successfully concluded its Special Meeting of Stockholders on Friday, January 14, 2022, as planned.

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a collaboration and research agreement with The Danish Cancer Society Research Center (DCRC) to support clinical development of Lantern’s acylfulvene class drug candidates, LP-100 and LP-184.

23andMe today provided an update on its collaboration with GlaxoSmithKline plc (“GSK”).

NRx Pharmaceuticals (Nasdaq: NRXP) today announced enhancements to its Expanded Access and Right to Try programs.